Yosef Refaeli

Taiga Biotechnologies, Inc. develops novel therapies for complex diseases including cancers, infectious agents, and hematologic conditions. Its programs include bone marrow engraftment enhancer, ebola problem, immune based therapies, monoclonal antibodies, and red blood cell pharming. The company was founded by Yosef Refael and Brian Turner in 2006 and is headquartered in Aurora, CO.

Taiga Biotechnologies, Inc. develops novel therapies for complex diseases including cancers, infectious agents, and hematologic conditions. Its programs include bone marrow engraftment enhancer, ebola problem, immune based therapies, monoclonal antibodies, and red blood cell pharming. The company was founded by Yosef Refael and Brian Turner in 2006 and is headquartered in Aurora, CO.

Taiga Biotechnologies, Inc. develops novel therapies for complex diseases including cancers, infectious agents, and hematologic conditions. Its programs include bone marrow engraftment enhancer, ebola problem, immune based therapies, monoclonal antibodies, and red blood cell pharming. The company was founded by Yosef Refael and Brian Turner in 2006 and is headquartered in Aurora, CO.

Taiga Biotechnologies, Inc. develops novel therapies for complex diseases including cancers, infectious agents, and hematologic conditions. Its programs include bone marrow engraftment enhancer, ebola problem, immune based therapies, monoclonal antibodies, and red blood cell pharming. The company was founded by Yosef Refael and Brian Turner in 2006 and is headquartered in Aurora, CO.

Taiga Biotechnologies, Inc. develops novel therapies for complex diseases including cancers, infectious agents, and hematologic conditions. Its programs include bone marrow engraftment enhancer, ebola problem, immune based therapies, monoclonal antibodies, and red blood cell pharming. The company was founded by Yosef Refael and Brian Turner in 2006 and is headquartered in Aurora, CO.